Anzeige
Mehr »
Login
Freitag, 10.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
100 % Anstieg in zwei Tagen: Das technische Signal, das Wall Streets Bären in Panik versetzt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
859 Leser
Artikel bewerten:
(2)

Royal Philips: Philips showcases comprehensive cardiology portfolio designed to increase physician confidence and efficiency in diagnosing and treating cardiac disease at ACC/WCC 2023

Finanznachrichten News

March 2, 2023

  • Philips Ultrasound Compact System 5500 CV adds to Philips' cardiology portfolio bringing diagnostic quality cardiac imaging to the patient bedside
  • Clinical evidence presented by leading clinical partners shows how utilization of Philips cardiology solutions improves patient care

Amsterdam, the Netherlands -Royal Philipsevent (ACC.23/WCC, March 4 - 6, New Orleans, USA). Philips' cardiology portfolio addresses ever-increasing demand for cost-effective diagnosis, treatment, monitoring, and management of patients with heart conditions such as coronary artery disease, structural heart disease, arrhythmia, and heart failure.

Highlighted introductions to the portfolio include the company's latest compact portable ultrasound platform - Philips Ultrasound Compact System 5500 CV, its spectral-detector based CT scanner, Philips Spectral CT 7500, and Philips Intracardiac Echocardiography Catheter - VeriSight Pro 3D ICE.

Evidence-based cardiology innovation
In line with Philips' commitment to supporting its innovations with clinical evidence, three of the company's clinical partners will present the results of clinical studies at ACC.23/WCC that could help inform clinical guidelines.

  • Dr. Eric Secemsky, Director of Vascular Intervention at Beth Israel Deaconess Medical Center (Boston, MA, USA) will present the results of a high-quality real-world evidence study of data for over a million U.S. Medicare patients to evaluate trends in the use of, and outcomes associated with, intravascular imaging (IVI) during percutaneous coronary intervention (PCI) procedures. Philips is a leader in IVI with its intravascular ultrasound (IVUS) solutions (https://www.usa.philips.com/healthcare/education-resources/technologies/igt/intravascular-ultrasound-ivus/coronary/clinical-evidence).
  • Dr. Mohamad Alkhouli, Professor of Medicine at Mayo Clinic School of Medicine (Rochester, MN, USA) will present a study on the real-world performance and safety of the Philips Intracardiac Echocardiography Catheter - VeriSight Pro (https://www.abstractsonline.com/pp8/#!/10674/presentation/11322) 3D ICE.
  • Dr. Sean Pokorney, Assistant Professor of Medicine and Member of the Duke Clinical Research Institute at Duke University School of Medicine (Durham, NC, USA) will examine the hospitalization and healthcare expenditure benefits associated with guideline driven care and early extraction of infected cardiac implantable electronic devices (https://www.abstractsonline.com/pp8/#!/10674/presentation/19239) (CIEDs), for which Philips is the market leader in lead management devices.

All three clinical studies are part of more than 110 ongoing clinical studies that support Philips image-guided therapy solutions with clinical evidence.

Other highlighted innovations from its cardiology portfolio that Philips is showcasing at ACC.23/WCC are the company's advanced image-guided therapy platform Philips Image-Guided Therapy System - Azurion; Philips Interventional Applications Platform - IntraSightinterventional workspace; Philips IntelliSpace ECGproviding fast, easy access to ECGs from almost anywhere in the medical facility; and Philips Mobile Cardiac Telemetry - MCOTambulatory cardiac monitoring solution.

For a more complete overview with in-depth information of the Philips solutions showcased at ACC.23/WCC please see our backgrounder.

To connect with experts and learn more about Philips cardiology solutions, stop by Philips booth #338. The clinical study presentation by Dr. Mohamad Alkhouli will take place on March 4, 2023, 1:45 PM - 1:55 PMby registered users.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips.

Attachments

  • Philips Intracardiac Echocardiography Catheter - VeriSight Pro (https://ml-eu.globenewswire.com/Resource/Download/6d97574d-d680-4280-b227-408a5c3c826f)
  • Azurion image-guided therapy platform (https://ml-eu.globenewswire.com/Resource/Download/fa7eb275-27af-4f21-830e-1deea163dd8a)
  • Philips Ultrasound Compact System 5500 CV (https://ml-eu.globenewswire.com/Resource/Download/4f587d4f-21cc-4e24-9274-09de454bf590)
  • Philips Spectral CT 7500 (https://ml-eu.globenewswire.com/Resource/Download/7b34cf8c-7698-48ad-b9bc-9d8c0d665d9f)

© 2023 GlobeNewswire (Europe)
6 Richtige für 2025
Das Börsenjahr 2025 klopft schon an die Tür – und wie immer geht es um die Frage: Welche Aktien werden die großen Gewinner sein? Die Auswahl an Möglichkeiten ist riesig, doch nur ein paar echte Volltreffer stechen heraus.

Ob stabiler Dividenden-Lieferant, Tech-Pionier oder spekulative Wette im Krypto-Bereich – wir haben die Märkte für Sie ausgiebig durchforstet und präsentieren Ihnen 6 Unternehmen, die große Chancen auf außergewöhnliche Kurssteigerungen besitzen. Hier sind, speziell für Sie, Ihre „6 Richtigen“ für 2025.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche Unternehmen das Potenzial besitzen, im kommenden Jahr richtig durchzustarten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.